Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Univercells

Explore full profile

Designing biological solutions for healthcare providers making biologics available to everyone

Charleroi, BelgiumFounded 2013Biotech & Life Sciences
Revenue $1–10M Latest reported FY
Headcount <100 Current team size
Total funding $100–500M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Univercells and the history behind them.

About Univercells

Univercells is a biotechnology company focused on developing novel biomanufacturing platforms and solutions to make biologics affordable and accessible to all. Operating primarily in the biopharmaceutical sector, Univercells serves clients ranging from small biotech firms to large pharmaceutical companies. The company operates in the global market, addressing the critical need for cost-effective and scalable production of biologics, including vaccines and gene therapies.

Univercells' business model revolves around the development and commercialization of proprietary biomanufacturing technologies. These technologies are designed to simplify and scale up the production process, significantly reducing costs and time-to-market. The company generates revenue through the sale of these platforms, licensing agreements, and strategic partnerships with other biotech and pharmaceutical companies.

Univercells' innovative approach has attracted significant investment, including a Series C financing round, enabling further development and expansion of its technology platforms. The company's commitment to breaking down barriers in bioproduction is evident in its continuous efforts to enhance production capacity and efficiency.

Source: Dealroom company data

At a glance

Founded
2013
Headquarters
Charleroi, Belgium
Sector
Biotech & Life Sciences

Investors

22 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • Bill & Melinda Gates Foundation
  • Public Service of Wallonia

Series A6 investors entered at this stage

  • Takeda
  • Takeda Ventures
  • Korea Investment Partners
  • Global Health Investment Corporation
  • Inventures Investment Partners
  • Innovation Fund | Brussels

Series B and later14 investors entered at this stage

  • Gamma Biosciences
  • Bill Gates
  • SFPIM
  • Christian Dumolin
  • WE Venture
  • George Soros
  • Guido Vanherpe
  • Marc Speeckaert
  • Wallonie Entreprendre
  • Amerigo Capital
  • AdBio partners
  • In-Q-Tel
  • Adjuvant Capital
  • TCD Capital
Team profiled 17 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇧🇪 Belgium64.7%
🇨🇭 Switzerland11.8%
🇺🇸 United States5.9%
🇧🇷 Brazil5.9%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Univercells on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Univercells on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.